Truist analyst Richard Newitter lowered the firm’s price target on Medtronic (MDT) to $103 from $107 and keeps a Hold rating on the shares. The firm notes the company posted modest organic revenue and EPS upside, and reiterated FY26 guidance. Medtronic saw relatively strong performance, beating CNS across 3 of 4 segments, with Diabetes and Cardiovascular offsetting Neurosciences underperformance, Truist adds.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT: